New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
12:40 EDTALLT, BAC, S, AZN, MBI, CLWR, RIGL, ZAGG, BBYOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday, extending the slide that began late yesterday following Ben Bernanke's press conference. House Speaker John Boehner and Senate Majority Leader Harry Reid both held press conferences within about the last hour, bringing the fiscal cliff fight back to the forefront of investors' minds... ECONOMIC EVENTS: In the U.S., weekly jobless claims fell 29,000 to 343,000, versus expectations for a drop to 369,000. Producer prices in the month of November fell 0.8%, versus an expected decline of 0.5%. "Core" prices, excluding food and energy, rose 0.1%, which matched expectations. Retail sales rose 0.3% in November, which missed expectations for an increase of 0.5%. In Europe, the region's finance ministers approved the long-delayed release of financial aid to Greece. Also, an agreement was reached on the foundation of a true banking union with ECB oversight... COMPANY NEWS: Best Buy (BBY) jumped over 15% after Minneapolis' Star Tribune said the company's founder Richard Schulze may make a fully financed $5B-$6B buyout offer by the end of the week... Clearwire (CLWR) rose nearly 14% to $3.13 after Sprint (S) disclosed that it offered $2.90 per share for the remaining stake in the company it does not already own. Clearwire said that its talks with Sprint are ongoing... MAJOR MOVERS: Among the notable gainers were ZAGG (ZAGG), up 15% after announcing a $10M share repurchase program, and MBI (MBIA), up 6.5% following positive analyst commentary about the potential for a settlement with Bank of America (BAC). Among the noteworthy losers was Rigel Pharmaceuticals (RIGL), which fell almost 35% after an RA drug it is developing in partnership with AstraZeneca (AZN) failed to meet one of its endpoints in a trial. Shares of AstraZeneca, meanwhile, fell 2.6%. Also lower were shares of Allot Communications (ALLT), down over 11% following a downgrade to Hold at Wunderlich... INDICES: Near 12:30 pm ET, the Dow was down 19.89, or 0.15%, to 13,225.56; the Nasdaq was down 21.52, or 0.71%, to 2,992.29; and the S&P 500 was down 7.47, or 0.52%, to 1,421.01.
News For BBY;CLWR;S;ZAGG;MBI;BAC;RIGL;AZN;ALLT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 17, 2014
15:45 EDTBBYBest Buy remains a top pick for the holiday season at BofA/Merrill
Subscribe for More Information
10:15 EDTBACBank of America reports October default rate 2.81% vs. 2.93% last month
Reports October delinquency rate 1.94% vs. 1.92% last month.
09:37 EDTAZNAstraZeneca to host investor day
Subscribe for More Information
07:39 EDTBBYBest Buy price target raised to $42 from $35 at Stifel
Subscribe for More Information
07:16 EDTAZNMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
07:08 EDTAZNMedImmune presents positive Phase IIb data for mavrilimumab in RA
Subscribe for More Information
07:07 EDTAZNMedImmune presents new data in systemic lupus
Subscribe for More Information
07:05 EDTBBYBest Buy price target raised to $40 from $36 at RBC Capital
Subscribe for More Information
06:43 EDTAZNAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
November 16, 2014
13:36 EDTAZNAstraZeneca presents data from studies of lesinurad combined with allopurinol
Subscribe for More Information
November 14, 2014
17:07 EDTBBYSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
14:53 EDTAZNCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:53 EDTSOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
11:48 EDTBBYStocks with call strike movement; GILD BBY
Subscribe for More Information
10:26 EDTZAGGZAGG management to meet with Roth Capital
Subscribe for More Information
07:36 EDTBBYBest Buy price target raised to $36 from $32 at UBS
UBS raised its price target on Best Buy to $36 from $32 ahead of its Q3 results. The firm sees a favorable near-term set-up, citing the company's cash balances, selection of premium products, and focused strategy of promotions deployment and expenses. UBS reiterates its Buy rating on Best Buy shares.
07:14 EDTAZNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
07:16 EDTAZNBIT Congress to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use